Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allogene Therapeutics, Inc. (Nasdaq: ALLO) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Allogene files periodic reports and current reports that describe its AlloCAR T pipeline, financial condition, and key risks.
Among the most relevant filings for ALLO are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss clinical programs such as cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma, ALLO-329 in autoimmune disease, and ALLO-316 in renal cell carcinoma. These reports also include detailed risk factor sections covering topics like gene-editing technology, reliance on licensed TALEN-based platforms, and intellectual property disputes referenced in company disclosures.
Allogene also submits numerous current reports on Form 8-K to describe material events. Recent 8-K filings have furnished quarterly financial results, outlined changes to the ALPHA3 trial’s lymphodepletion regimen following safety review, and described third-party patent litigation involving Cellectis’s TALEN technology on which Allogene relies. Other filings document matters such as annual meeting voting results and the continued listing of ALLO common stock on The Nasdaq Stock Market LLC.
On Stock Titan, investors can use AI-powered tools to review these filings, surface key points, and understand how disclosures about clinical trial design, safety findings, intellectual property, and governance may relate to ALLO stock. The filings page is a central resource for tracking Allogene’s regulatory history, financial reporting, and formal statements about its allogeneic CAR T development strategy.
Allogene Therapeutics SVP and General Counsel Douglas Earl Martin reported new equity awards and a related share sale. On February 2, 2026, he was granted a stock option covering 539,072 shares of common stock at an exercise price of $1.87 per share. Twenty‑five percent of this option will vest on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments.
He also received 152,480 restricted stock units, each representing one share of common stock, which will vest in four equal annual installments starting February 2, 2026, subject to continued service. On the same date, he sold 22,900 shares of common stock at a weighted average price of $1.76 to cover tax withholding obligations from RSU vesting, and this was not a discretionary trade. After the sale, he directly beneficially owned 564,948 shares of common stock.
Allogene Therapeutics, Inc. SVP Finance Annie Yoshiyama reported new equity awards and a small tax-related share sale. On February 2, 2026, she received a stock option for 179,691 shares of common stock at an exercise price of $1.87 per share and an award of 50,827 restricted stock units (RSUs). The option vests 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments, while the RSUs vest in four equal annual installments starting from February 2, 2026, subject to continued service. On the same date, she sold 4,167 shares of common stock at a weighted average price of $1.72 solely to cover tax withholding on vesting RSUs, under a mandatory “sell to cover” arrangement, and reported owning 130,322 common shares directly afterward.
Allogene Therapeutics EVP of R&D Zachary Roberts reported equity award grants and a tax-related share sale. On February 2, 2026, he was granted a stock option for 718,763 shares of common stock at an exercise price of
Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.
Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.
ALLO had a Form 144 filed to permit the sale of 22,900 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/02/2026, to be sold on NASDAQ with an aggregate market value of $40,214.69.
The shares were acquired on 01/31/2026 as restricted stock vesting under a registered compensation plan, with compensation listed as the form of payment. The filing notes that 224,730,144 shares of common stock were outstanding.
A holder of ALLO common stock has filed a Rule 144 notice to sell 24,001 shares through Morgan Stanley Smith Barney LLC on or about 02/02/2026 on NASDAQ. The aggregate market value of the planned sale is listed as $42,188.96, with issuer shares outstanding of 224,730,144.
The shares were acquired as restricted stock vesting under a registered compensation plan from the issuer on 01/31/2026, in a non-cash transaction classified as compensation. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.
The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.
Allogene Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 4,167 shares of Allogene Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,177.66. The shares were acquired on January 31, 2026 through restricted stock vesting under a registered compensation plan.
The planned sale is expected to occur around February 2, 2026 on the NASDAQ exchange. As of the notice, 224,730,144 shares of Allogene common stock were outstanding, providing context for the relative size of this planned transaction.
A planned sale notice under Rule 144 covers 243,976 shares of Common Stock, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares have an aggregate market value of 438,522.46 and are part of a total of 224,730,144 shares outstanding.
The seller acquired these shares as restricted stock vesting under a registered plan from the issuer on 01/31/2026, treated as compensation. The approximate planned sale date is 02/02/2026, and the signer represents not knowing any undisclosed material adverse information about the issuer’s operations.
A holder of common stock has filed a Form 144 notice to potentially sell 16,823 shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $29,051.64. The issuer reports 224,730,144 shares of common stock outstanding.
The shares to be sold were acquired as restricted stock vesting under a registered plan on January 31, 2026, treated as compensation from the issuer. The same individual previously sold 786 common shares on November 17, 2025, generating gross proceeds of $958.92.